Showing posts with label alzheimer. Show all posts
Showing posts with label alzheimer. Show all posts

Friday, February 5, 2016

Diagnosis of dementia and Alzheimer's disease

So there isn't one stand-alone test that will show whether someone has dementia or Alzheimer's disease, since the typical symptoms like memory loss, confusion, and others, can have a whole slew of potential causes. That being said, it's not usually diagnosed until a complete medical assessment is performed. But what all does that entail? Well, first off, a healthcare professional might take a look at the patient's history.


They'll try to gather information from the patients themselves as well as from their friends and family. They'll probably ask questions like what kind of symptoms have you noticed? Or when did you start noticing them? How often do they happen?

And have you noticed them getting any worse? They'll also try to evaluate the patient's emotional state. A lot of the time the patient might be completely unaware of their current state or they might be in denial about it. And this can be tough because sometimes even other family members will deny its progression because many of the early signs of dementia also tend to look just like normal signs of aging.

And this is just another reason why it makes diagnosis of dementia very, very hard and why we have to rely on other methods of diagnosis as well. So a physical examination can also be done. In these, your doctor will check things like your hearing or your eyesight, your heart and your lungs, your temperature, your blood pressure, and your pulse. And they may also take things like blood and urine samples.

Information from these can help the doctor figure out if there are any other underlying health issues that are causing or contributing to the dementia itself, like heart problems and vascular dementia or if there's another condition that's mimicking symptoms of dementia, since other conditions like anemia or depression, infection, diabetes, kidney disease, and others can also cause dementia-like symptoms, like confused thinking and memory problems. But besides physical exams, a neurological evaluation may also be done.

And this'll look at the patient's nervous system and will test things like balance and sensory function using lights and also your reflexes, using that tiny hammer and lightly tapping it on the knee. The doctor might also give the patient a cognitive or a neuropsychological test, which are used to kind of objectively measure the patient's current memory, language skills, math skills, and other abilities as they relate to mental function. And one big one's called the mini mental state examination or MMSE.

And this test can be particularly helpful in diagnosing dementia because it looks at orientation, memory, and attention. For example, it might ask to follow verbal or written commands or write down a sentence spontaneously or copy a complex shape. And depending on the score, a certain level of dementia might be suggested. Scores of about 20 to 24 suggest mild dementia, 13 to 20 suggests moderate dementia, and less than 13 would suggest a severe case of dementia. And typically patients with Alzheimer's disease tend to drop two to four points on average every year.

Another more simple test that might be administered is called the mini-cog test. In this test the patient is asked to name three objects and then repeat them back to the doctor, like car, chair, and mug. For the next part, the patient is asked to draw an analog clock and also asked to draw a specific time. Thirdly, the patient's asked what those three objects initially were, car, chair, and mug. If the patient fails one or all of these tests, it might suggest signs of dementia and may require a further evaluation. Another potential test is the psychiatric evaluation or mood assessment.

They'll try to assess the patient's current level of well-being, looking for signs of depression or other mood disorders that can also contribute to symptoms that overlap with dementia symptoms. Finally, the patient might have brain scans. With a brain scan the brain's actually visualized through techniques like computed tomography or CT scans or magnetic resonance imaging or MRI.

And there are several reasons why we might want one these performed. They might be useful in identifying larger masses, like tumors, that can be contributing to the cognitive impairment. But it might also help in making a differential diagnosis, meaning that we'll try to look to figure out what type of dementia is at play. Sometimes by looking at where the most atrophy of brain tissue is localized, we can figure out what type of dementia it is.

For example, atrophy that's localized to the hippocampus might suggest Alzheimer's disease or the frontal lobe might suggest frontotemporal dementia or vascular pathologies that are visualized might suggest vascular dementia. And another reason for a brain scan might be to monitor disease progression. Several imaging sessions over several years might show how the brain has changed over time. More atrophy might be indicative of disease progression whereas if the atrophy has stayed the same over time, it might suggest that a different or a more static cognitive disease is at play.

Finally, imaging is really, really valuable for research purposes, especially with respect to structural imaging and figuring out which structures are affected first by the disease in addition to any chemical processes that might be involved. And this information helps physicians and researchers alike understand dementia as a disease and develop more effective treatments in the future.

Treatment of dementia and Alzheimer's disease

Scientists and physicians continue to learn more and more about Alzheimer's disease and dementia in general, but unfortunately, they still haven't found a cure. With that said, though, there are medications that can help lesson the symptoms of dementia, like memory loss and confusion. Currently, all the medications approved by the Food and Drug Administration or the FDA are aimed at either one of two neurotransmitters:

acetylcholine or glutamate. The first class of drugs are cholinesterase inhibitors. Acetylcholine is a really important neurotransmitter in our brain and nervous system. Even though it has important functions in other parts of our body, in our brain, it helps our neurons communicate. And it's this communication of our neurons that allows our brain to think and do things like sustain attention, sense things, learn and remember things.

Okay, so, say we have these two neurons here that are trying to communicate, one transmitting neuron and one receiving neuron. The transmitting neuron releases the neurotransmitter acetylcholine, which then binds to an acetylcholine receptor on the receiving neuron. And this is how these two neurons communicate, right? To sort of regulate this process, though, you have this enzyme that constantly breaks down the acetylcholine that's being released and this sort of makes sure that too much doesn't build up.

And this guy is called acetylcholinesterase, and it breaks acetylcholine down into acetic acid and choline. Think of acetylcholinesterase like Pac-Man and all of these acetylcholines as the little dots that he eats. He's constantly going around eating the dots, but some of them may get by to communicate between the neurons. So, it's like this balance, right, of some of the dots being eaten and some communicating.

Acetylcholinesterase is a type of cholinesterase. So, if we throw a cholinesterase inhibitor into the mix, like the ghost in Pac-Man, then we inhibit or stop our Pac-Man from doing his job of eating the dots, right? Which means more of these dots build up, and we tilt the balance in favor of the dots or acetylcholine. Now, patients with Alzheimer's disease, though, already have decreased levels of dots in the first place. So, with Pac-Man there, they have even less.

But if we inhibit Pac-Man, then we have less dots being eaten, right? And so, we end up with more active acetylcholine. And by doing this, by stopping the enzyme that breaks down acetylcholine, we can help neurons communicate in people with Alzheimer's disease. And this medication can help delay worsening of dementia symptoms for about six to 12 months on average, for about half of the patients that take them.

And although they're usually pretty well tolerated, some side effects can include nausea, vomiting, and loss of appetite. All right, so that's the first type of medication for Alzheimer's disease. The second type targets the neurotransmitter glutamate, and is called memantine. Just like acetylcholinesterase inhibitors, memantine is prescribed to help patients with symptoms related to memory, attention, reasoning, and language skills.

Instead of acetylcholine, though, now we focus on this neurotransmitter called glutamate. Glutamate, when at normal levels, actually helps our learning and memory, and is considered an excitatory neurotransmitter. When glutamate levels get too high, though, it's actually toxic to the cell. And we use the word called excitotoxicity, where the cell gets actually too stimulated and may die as a result.

Having too much glutamate is thought to be one possible way that people with Alzheimer's disease lose nerve cells and therefore have problems learning and remembering new things. So, again, we've got our two neurons transmitting and receiving, right? And we have this receptor on the receiving neuron called the NMDA receptor, which is also like this channel or gateway that lets in ions to the receiving cell.

Now, this gateway lets them in when glutamate binds to it. So, if there's too much glutamate and this gateway is always open, then the receiving neuron can suffer from excitotoxicity, because it's like always being stimulated. Now, memantine blocks this receptor for glutamate, so it keeps this channel closed more. And when it's closed more, we bring down the stimulation to normal levels and avoid killing the cell by overstimulating it.

Think of glutamate like this key that opens the door to this party down here, letting all the ions in. If too many get in, though, the party gets too big and too crowded and out of control. If we put a different lock on the door, memantine, then the key won't open it, and the party stays at reasonable levels. Now, memantine is used most often to treat moderate to severe Alzheimer's disease, and will often be taken alongside cholinesterase inhibitors.

Some side effects can be things like headache, confusion, and dizziness. So, switching gears a little bit, other forms of treatment often target behavioral symptoms, like agitation, irritability, aggression, and anxiety. Usually, it's preferred to focus on treatments that don't use medications for these, though, like behavioral modification, since a lot of medications intended to treat behavioral symptoms can actually increase confusion and can even be associated with increased mortality.

Thursday, February 4, 2016

Cholesterol and Alzheimer’s disease

Millions suffer from Alzheimer’s disease. And the available and foreseeable treatments are disappointing at best. Given the absence of disease-modifying treatments, there has been growing interest in effective strategies for the prevention of the disease in the first place. Even if we were able to just delay the onset by as little as one year, we could potentially prevent more than nine million cases over the next 40 years.

Once cognitive functions are lost in Alzheimer’s disease patients, they may be lost forever. Consequently, prevention, rather than a cure for Alzheimer’s Disease, appears as a more realistic strategy to offset the catastrophic impact of this dementia. Considerable evidence now indicates that Alzheimer’s disease is primarily a vascular disorder, based on a number of lines of evidence that point towards impaired circulation of blood to the brain Vascular risk factors such as high cholesterol can be thought of as a ticking time bomb to Alzheimer’s Disease. What’s bad for the heart may be bad for the mind.

Traditionally, there have been two competing theories for the cause of Alzheimer’s, the amyloid cascade model that implicates the buildup of amyloid plaques within the brain, and the vascular model that argues that is the lack of adequate blood flow to the brain due to atherosclerosis. We now realize they are not mutually exclusive, and that arterial disease can set up a vicious cycle in which atherosclerotic plaques in the arteries may contribute to Alzheimer’s plaques in the brain.

Although at times portrayed as tantamount to poison, cholesterol is an essential structural component of all our cells,  but if there’s too much it can become a major factor contributing to various diseases including coronary artery disease, stroke, and neurodegenerative diseases like Alzheimer’s. Too much cholesterol in our blood is unanimously recognized to be a risk factor for the development Alzheimer’s disease, and cholesterol may play an active role in the progression of Alzheimer’s as well. Autopsy studies have found that Alzheimer’s brains have significantly more cholesterol than normal brains, and specifically appears to accumulate in the Alzheimer brain plaques.

But we used to think the pool of cholesterol in the brain was separate from the pool we had in our blood, but there is now growing evidence to the contrary. For example, LDL may be able to cross the blood–brain barrier into the brain. So a high-fat diet may not only increase cholesterol levels in the blood,  but also the influx of cholesterol into the central nervous system. In addition, having high cholesterol may even damage the blood brain barrier itself and allow for even more cholesterol to flow into the brain, providing the missing link between high cholesterol and Alzheimer’s. Individuals with higher cholesterol levels at midlife have a higher risk of going on to develop Alzheimer’s disease.

A cholesterol over 250 could potentially triple the odds of Alzheimer’s. And now we have high-tech PET scanning of the brain that can directly correlate the amount of so-called bad cholesterol in our blood with the amount of amyloid build up in our brain. You can do it right in a petri dish. Adding cholesterol makes them churn out more the amyloid that makes up Alzheimer plaques, whereas removing cholesterol can decrease the level of amyloid released from cells. In addition, amyloid degradation is less efficient, clearing amyloid is less efficient in a high cholesterol environment. Cholesterol can then help seed the clumping of the amyloid.

Using an electron microscope you can see the clustering of amyloid fibers  on and around little microcrystals of cholesterol. Once in the brain, cholesterol can also undergo auto-oxidation, causing the formation of highly toxic free radicals. So having high cholesterol levels in the blood is thought to increase the risk of dementia not only by inducing atherosclerosis and impairing blood flow, but may directly affect the neurodegeneration within the brain. In conclusion, excess dietary cholesterol could in principle contribute to the development of Alzheimer’s disease, and the evidence linking high cholesterol to Alzheimer’s appears to be steadily mounting. Of course, some of this work was paid for by drug companies hoping to capitalize on Alzheimer’s with cholesterol-lowering statin drugs;

ironic, since statins themselves can cause cognitive impairment. Though rare, statin side-effects may include short- and long-term memory loss, behavioral changes, impaired concentration and attention, paranoia, and anxiety, as early as five days after starting the drugs, but sometimes even months later, though folks should recover within a month of stopping the drugs.

A better strategy then, may be to change the lifestyle factors that lead to the high cholesterol in the first place, in particular saturated fat from the diet, but it’s not enough for us to just tell our individual patients. Systematic implementation of educational campaigns promoting radical changes in cultural and societal values may be necessary to adopt Alzheimer’s defeating strategies by patients in a broader sense, and such actions may provide potentially huge dividends by preventing both cardiovascular disease and dementia, two of our leading causes of death.

Alzheimer's disease: Plaques and tangles

If we take a look at the brain tissue that's been affected by Alzheimer's Disease under a microscope, there's almost always two common factors that we'll see, and these are called plaques and tangles. Let's just look at these plaques for a minute. Well, actually, they're called beta-amyloid plaques. Amyloid is the name we use for fragments of proteins, so it's like not the whole protein, just little bits of it. And these are produced normally in the body. Beta-amyloids are protein fragments that have been snipped off of the larger protein by specific enzymes.

So, you have your neuron with this protein called amyloid precursor protein sort of sticking out through the cell's membrane. And so, how beta-amyloid forms is when these enzymes swing by and chop off our beta-amyloid protein fragment. These little beta-amyloid snippets are somewhat sticky, and they'll start to clump together. And as they clump, they mix with other molecules and even other neurons, forming what's eventually called beta-amyloid plaques.

Now, it's thought that these clumps of plaques, especially the smaller ones, may interfere with the cell-to-cell communication between the neurons, essentially blocking the signal at the synapse. It's also thought that they might activate the immune response as well, which triggers inflammation and also tells your immune cells to root out and destroy the disabled cells.

Now, it's super, super important to note that this process is still not very well understood. It's especially unclear whether beta-amyloid plaques themselves contribute to causing Alzheimer's Disease or if they're essentially just a result of the progression of Alzheimer's Disease.

So, those are the plaques. Now, let's talk about these tangles. Another more fancy name you might hear is neurofibrillary tangles. And these, unlike the beta-amyloid plaques, actually show up inside the neurons.

So, usually, healthy neurons are internally supported by and partly made up of these structures called microtubules. These microtubules are like tracks that guide nutrients and other molecules from the cell's body down to the cell's axon, which is usually connected to another neuron. And this is basically how the neighboring neurons communicate.

So, you could think of these microtubules like rails that carry a mining cart with a bunch of sweet ores and minerals, which are like the nutrients and the messages, to the other miners, which are like the other neurons. Now, a special protein simply called "tau" binds and stabilizes our rails. Kind of like how railroad spikes keep our rails in place, these tau proteins keep our microtubules in place.

In Alzheimer's Disease, these railroad spikes, the tau proteins, are chemically changed and basically aren't the right type of spikes. And instead of holding the tracks together, they pair with other tau proteins. And when they do that, they get all tangled up with each other.

And since the tracks don't have anything holding them together anymore, what do they do? Well, they start to fall apart, and so our microtubules fall apart, and these tau proteins become tangled. And since our track is all messed up, this disrupts our whole transport system. And when this happens, we call them neurofibrillary tangles.

Since the tangles are sort of like these thread-like fibers or fibrils, we say "fibrillary." And since they're in the brain, we say that they're "neurofibrillary." And it's thought that the disruption of our rail system causes some communication issues between our neurons.

And since they can't communicate or transport our materials, they eventually are decomissioned and undergo nerve cell death. Now, these plaques and tangles can be found in brains of many elder people, but they're found to a much,  much greater extent in the brains of those with Alzheimer's Disease.

And for Alzheimer's, they tend to start forming and spread from the cortex in a pretty predictable way, as Alzheimer's progresses. The earliest areas affected are usually those associated with learning and memory, here in the temporal lobe.

And as it spreads and more neurons are affected, it usually goes up to the frontal lobe, where thinking and planning become affected. And then, more of the temporal lobe, as speaking and communicating become affected as well.

And then, it kind of moves up into your parietal lobe, where your sense of where your body is in relation to objects around you becomes affected. In severe and late-stage Alzheimer's Disease, these plaques and tangles have spread throughout most of the cortex.

And as this happens, the cortex gets seriously, seriously damaged. And due to this widespread cell death, the brain actually shrinks dramatically. But since Alzheimer's progresses at different rates for every patient, the rate of spreading of these plaques and tangles varies a lot from patient to patient.

Stages of dementia and Alzheimer's disease

So, Alzheimer's disease, vascular dementia, Lewy body dementia, and every other type of dementia causes damage to your brain cells, right, which, in turn, causes some difficulties with various things your brain controls, like memory, language, reasoning, and judgement. But a lot of the time, these signs and symptoms can present themselves slightly differently.

Since Alzheimer's disease accounts for the majority of dementia cases and the other forms can often overlap anyways, the main focus here will be on the symptoms and progression of Alzheimer's disease. Dementia in Alzheimer's disease typically develop over the course of years, but the speed at which it develops can vary pretty dramatically, from four years in some patients, eight in others, and even as high as 20 years in some cases. We're going to go through some of the general stages of progressing Alzheimer's disease, but considering that it's such a gradual disease, it's actually really tough to classify this progression.

And it's important to remember that there are no clear-cut or well-defined stages, and many of these stages that we'll go through can even overlap. But, with that said, there are a few models that are used for the progression of Alzheimer's disease, and we're going to sort of combine the definitions from a more broad three-stage model and also the more specific seven-stage Reisberg Scale. So, from the three-stage model, we have the very early to mild stages of Alzheimer's, lasting about two to seven years. And then, if we look at the Reisberg Scale, stage one is simply no impairment.

So, your memory and cognitive abilities appear normal, especially to everyone else. If there are any impairments, they might only be slightly apparent to the patient themselves. Stage two, however, is a very mild cognitive decline. So, maybe they have some trouble remembering recent events or information, but it could be more subtle things like forgetting a word or misplacing things.

And, again, at this stage, these lapses and changes in thinking aren't usually detected by friends, family, or even medical personnel, especially considering half of all people over 65 begin noticing problems with concentration and word recall just as a normal consequence of aging. Stage three is signs of early confusion and mild cognitive impairment. At this point, subtle difficulties can start to impact their daily life. The patient might consciously or even subconsciously try to hide these issues.

They might have trouble retrieving words, remembering what was just said or read, and planning and organizing, which can all start to affect life at home or at work. It could still be difficult, though, to diagnose Alzheimer's at this very early stage. Now, stage four is considered mild Alzheimer's disease. This stage lasts about two years. And during these two years, things like financials and math start to become very challenging.

And the ability to remember recent events and what was just learned becomes increasingly difficult. The patient might have trouble carrying out tasks, especially if there are specific sequences, like cooking or driving.

But the patients are still usually able to recognize their family and friends, although a diagnosis at this stage is usually accurate. Stage five is considered early dementia to moderate Alzheimer's disease. In this stage, cognitive decline starts to become more drastic, and the patient requires assistance.

They'll probably have trouble remembering things like address or phone number and can be disoriented very easily regarding the time or place. Decision and judgement skills can also be affected, like choosing the appropriate clothes for the day or season. And so, the patient may need increased supervision. This stage can last an average of about 1.5 years.

Stage six is considered moderately severe Alzheimer's disease, and in this stage, there's a significant lack of awareness of present events, and this inability to remember the past and carry on a conversation, and they'll likely need help with basic daily tasks like getting dressed, eating, and going to the bathroom. The patient will likely be unable to recall names of family members but will likely know that they're familiar. This stage lasts about 2.5 years. In the final stage or stage seven, speech becomes severely limited, and we see a serious decline  in basic abilities.

Even movement abilities begin to be affected as the disease has started to spread to those areas of the brain, so eating, walking, sitting, or even standing up all start to fade.  And patients will likely need extensive assistance eating and drinking, as they can lose the ability to discern when they're thirsty or hungry. And so they need total assistance around the clock for all functions of daily life and care.

And at this stage, due to these inabilities, they become much more susceptible to secondary complications, diseases and infections, especially pneumonia and falls. And this final stage can last from one to two and a half years. But, again, it's very important to stress the flexibility in this timeline, in these stages. Not all patients with Alzheimer's will experience this exact progression, and some may deviate significantly from the expected duration with each stage and the disease itself.